Switching Long‐Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1‐Year <scp>OASISplus</scp> Results
In patients who switched from another LTP, donidalorsen was well tolerated and improved long-term HAE attack rates, quality of life, and disease control.
Authors
- A. Banerji
- Sabrina Treadwell
- Selina Gierer (ORCID: https://orcid.org/0000-0001-5186-3410)
- Tao Lin (ORCID: https://orcid.org/0000-0003-3647-0488)
- Kenneth B. Newman
- Joshua S. Jacobs
- Jonathan A. Bernstein
- Francesca Perego
- Laura Bordone
- Andrew Smith
- Danny M. Cohn
- Aaron Yarlas
- William R. Lumry
- Marc A. Riedl
- H. James Wedner
- Timothy Craig
- Michael E. Manning
Institutions
- La Jolla Institute for Immunology (US)
- Washington University in St. Louis (US)
- Ionis Pharmaceuticals (United States) (US)
- University of California San Diego (US)
- Massachusetts General Hospital (US)
- Istituti Clinici Scientifici Maugeri (IT)
- Allergy, Asthma and Clinical Research Center (US)
- Amsterdam Neuroscience (NL)
- Vinmec Times City International Hospital (VN)
- Bernstein Clinical Research Center (US)
- University of Kansas Medical Center (US)
- Scottsdale Research Institute (United States) (US)
- VinUniversity (VN)
- Allergy Associates Research Center (US)
- Amsterdam University of Applied Sciences (NL)
- Penn State Milton S. Hershey Medical Center (US)
- University of Amsterdam (NL)
Publication Details
- Journal
- Allergy
- Published
- 2026-03-14
- DOI
- https://doi.org/10.1111/all.70294
- Primary Topic
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Type
- article
- Field-Weighted Citation Impact
- 0.00